公开(公告)号：US12130296B2

公开(公告)日：2024-10-29

申请号：US17513568

申请日：2021-10-28

申请人： SANIFIT THERAPEUTICS S.A.

发明人： Joan Perello Bestard ,  Ciriaco Maraschiello De Zuani ,  Irene Lentheric ,  Paula Mendoza De Las Heras ,  Fernando Tur Espinosa ,  Eva Tur Tur ,  Maximo Encabo Alarcon ,  Eva Martin Becerra ,  Maria de Mar Benito Amengual ,  Bernat Isern Amengual

IPC分类号： G01N33/94 ,  C07K1/18 ,  G01N33/50 ,  G01N33/53

CPC分类号： G01N33/94 ,  C07K1/18 ,  G01N33/50 ,  G01N33/5005 ,  G01N33/5308 ,  G01N2496/00 ,  G01N2560/00 ,  Y10T436/163333

摘要： The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

公开(公告)号：US12129492B2

公开(公告)日：2024-10-29

申请号：US17343411

申请日：2021-06-09

申请人： D. Lansing Taylor ,  Albert Gough ,  Larry Vernetti

发明人： D. Lansing Taylor ,  Albert Gough ,  Larry Vernetti

IPC分类号： C12N5/071 ,  B01L3/00 ,  C12M1/42 ,  C12M3/06 ,  G01N33/50

CPC分类号： C12N5/0697 ,  B01L3/502715 ,  B01L3/502761 ,  C12M23/16 ,  C12M35/08 ,  C12N5/067 ,  G01N33/5067 ,  G01N33/5082 ,  B01L2300/0636 ,  C12N2502/11 ,  C12N2502/14 ,  C12N2502/28 ,  C12N2510/00 ,  C12N2513/00 ,  C12N2533/50 ,  C12N2533/54

摘要： Microfluidic devices for modeling three-dimensional tissue structures and methods for making and using the same are described herein.

公开(公告)号：US20240353396A1

公开(公告)日：2024-10-24

申请号：US18653887

申请日：2024-05-02

申请人： Brown University

发明人： Gregorio Valdez

IPC分类号： G01N33/50 ,  G01N15/01 ,  G01N15/1434 ,  G01N15/149 ,  G01N33/68

CPC分类号： G01N33/5058 ,  G01N15/1434 ,  G01N33/68 ,  G01N15/01 ,  G01N15/149 ,  G01N2333/43595 ,  G01N2333/705

摘要： The invention provides molecular tools to visualize, isolate, and manipulate the glial cells that are necessary for the formation, stability, and function of the synapse. The inventors identified a unique gene expression signature that distinguishes perisynaptic Schwann cells from all other Schwann cells. Using a combinatorial approach and coëxpressing two different fluorescence proteins, each using a different promoter, only those glial cells associated with the neuromuscular synapse are labeled.

公开(公告)号：US20240350600A1

公开(公告)日：2024-10-24

申请号：US18754670

申请日：2024-06-26

申请人： ARAVAX PTY LTD

发明人： ROBYN O'HEHIR ,  JENNIFER ROLLAND ,  SARA PRICKETT

IPC分类号： A61K39/00 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/35 ,  G01N33/50

CPC分类号： A61K39/001 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/35 ,  G01N33/5005 ,  A61K2039/57

摘要： The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.

公开(公告)号：US20240350599A1

公开(公告)日：2024-10-24

申请号：US18616880

申请日：2024-03-26

申请人： ARAVAX PTY LTD

发明人： ROBYN O'HEHIR ,  JENNIFER ROLLAND ,  SARA PRICKETT

IPC分类号： A61K39/00 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/35 ,  G01N33/50

CPC分类号： A61K39/001 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/35 ,  G01N33/5005 ,  A61K2039/57

摘要： The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.

公开(公告)号：US12123000B2

公开(公告)日：2024-10-22

申请号：US16972152

申请日：2019-06-14

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  UNIVERSITY COLLEGE LONDON ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  UNIVERSITÉ DE CAEN NORMANDIE ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE CAEN

发明人： Marie-Pierre Gratacap ,  Jean Darcourt ,  Bart Vanhaesebroeck ,  Gaëtan Chicanne ,  Bernard Payrastre ,  Vincent Larrue ,  Romain Solinhac ,  Aude Jaffre ,  Denis Vivien ,  Typhaine Anquetil

IPC分类号： A61K31/00 ,  A61P9/10 ,  C12N15/113 ,  G01N33/50

CPC分类号： C12N15/1137 ,  A61P9/10 ,  G01N33/5064 ,  C12N2310/14 ,  C12N2310/531

摘要： Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.

公开(公告)号：US12122821B2

公开(公告)日：2024-10-22

申请号：US16510220

申请日：2019-07-12

申请人： H. LUNDBECK A/S

发明人： Brian Baker ,  Jeffrey T.L. Smith ,  John Latham

IPC分类号： C07K16/18 ,  A61K39/00 ,  C07K16/26 ,  G01N33/50 ,  G01N33/66

CPC分类号： C07K16/18 ,  G01N33/5038 ,  G01N33/5088 ,  G01N33/66 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/76 ,  G01N2333/5753

摘要： The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

公开(公告)号：US12121534B2

公开(公告)日：2024-10-22

申请号：US17469530

申请日：2021-09-08

申请人： The General Hospital Corporation

发明人： Raul Mostoslavsky ,  Sita Kugel ,  Anders M. Naar

IPC分类号： A61K31/713 ,  C12N15/113 ,  C12Q1/34 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/574

CPC分类号： A61K31/713 ,  C12N15/1135 ,  C12Q1/34 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/57438 ,  G01N33/57476 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/82 ,  G01N2333/98

摘要： It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.

公开(公告)号：US20240345069A1

公开(公告)日：2024-10-17

申请号：US18760331

申请日：2024-07-01

申请人： ENERGESIS PHARMACEUTICALS, INC.

发明人： OLIVIER D. BOSS ,  JEAN-PAUL GIACOBINO

IPC分类号： G01N33/50 ,  A61K31/4439 ,  C12N5/077 ,  C12N5/0775

CPC分类号： G01N33/5061 ,  A61K31/4439 ,  C12N5/0653 ,  C12N5/0667 ,  G01N33/5023 ,  G01N33/5044 ,  C12N2501/01 ,  C12N2501/385 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/13 ,  G01N2800/04 ,  G01N2800/042

摘要： Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of or the making of medicaments for the treatment of metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia.

公开(公告)号：US20240345068A1

公开(公告)日：2024-10-17

申请号：US18644702

申请日：2024-04-24

申请人： ALCHEME BIO INC.

发明人： Vanessa Small

IPC分类号： G01N33/50 ,  G01N30/02 ,  G01N30/86

CPC分类号： G01N33/5041 ,  G01N30/8651 ,  G01N33/5097 ,  G01N2030/025 ,  G01N2030/027

摘要： Systems for cellular attribute alignment of a base cellular agriculture product with a reference product include first data including a compositional profile of a reference product having a cellular attribute of interest, second data including a compositional profile of a base cellular agriculture product produced to emulate the cellular attribute of interest of the reference product, and processing circuitry configured to identify one or more target compounds in the reference product affecting the attribute of interest, determine at least one compositional gap in the base cellular agriculture product compared to the reference product, and provide an adjustment to a manufacturing process or a manufacturing component for the base cellular agriculture product to reduce or eliminate the at least one compositional gap in the base cellular agriculture product affecting the attribute of interest to produce an enhanced cellular agriculture product. Methods and cellular agriculture products made therefrom are also provided.